Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development

被引：100

作者：

Blume-Kohout, Margaret E. ^{[1
,2
]}

Sood, Neeraj ^{[3
,4
]}

机构：

[1] Univ New Mexico, Robert Wood Johnson Fdn Ctr Hlth Policy, Albuquerque, NM 87131 USA

[2] Univ New Mexico, Dept Econ, Albuquerque, NM 87131 USA

[3] Univ So Calif, Schaeffer Ctr Hlth Policy & Econ, UGW Unit A, Los Angeles, CA 90089 USA

[4] Univ So Calif, Dept Pharmaceut Econ & Policy, UGW Unit A, Los Angeles, CA 90089 USA

来源：

JOURNAL OF PUBLIC ECONOMICS | 2013年 / 97卷

关键词：

Research and development; Innovation; Pharmaceutical industry; Medicare Part D; PRESCRIPTION DRUG COVERAGE; INDUSTRY; PRICES;

D O I：

10.1016/j.jpubeco.2012.10.003

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

Recent evidence suggests that Medicare Part D increased prescription drug use among seniors, and increased pharmaceutical firms' revenues from sales. Previous studies also indicate that increases in market size induce pharmaceutical innovation. This paper assesses the impact of the Medicare Part D legislation on pharmaceutical research and development (R&D), using time-series data on the number of drugs entering preclinical and clinical development by therapeutic class and phase. We find that the passage and implementation of Medicare Part D is associated with significant increases in pharmaceutical R&D for therapeutic classes with higher Medicare market share. (C) 2012 Elsevier B.V. All rights reserved.

引用

页码：327 / 336

页数：10

共 30 条

[1]

Abrantes-Metz R. M., 2005, J PHARM FINANC ECON, V14, P19, DOI DOI 10.1300/J371v14n04_03

[2] Market size in innovation: Theory and evidence from the pharmaceutical industry [J].